Acute kidney injury after lung transplantation: prediction, prevention, and management Authors: Chongyang Ye, Jian Huang, Tingting Ye, Li Ke, XianLiang Jiang, Chunyan Zhu Published: 2025 ABSTRACT AbstractAcute kidney injury (AKI) following lung transplantation is a significant complication that affects postoperative outcomes and survival rates among patients. This review provides a comprehensive overview of the mechanisms underlying the occurrence of AKI post-lung transplantation, identifies key risk factors, and discusses various predictive models that have been developed in this field. Moreover, we explore comprehensive preventive strategies and management approaches that are crucial for optimizing patient care. By analyzing relevant literature, we aim to highlight the importance of early recognition and intervention to improve postoperative results for lung transplant recipients. This synthesis of current knowledge not only serves to inform clinical practice but also underscores the need for continued research in this critical area. Introduction Lung transplantation is a critical intervention for patients suffering from end-stage lung diseases, providing a potential cure when other treatments fail. However, despite advancements in surgical techniques and perioperative care, lung transplantation is associated with a significant incidence of postoperative complications, particularly acute kidney injury (AKI). The occurrence of AKI in lung transplant recipients ranges from 30% to 50%, which can adversely affect both short-term and long-term patient outcomes, including survival rates and quality of life [1,2]. Understanding the risk factors, prevention strategies, and management of AKI is vital for improving the prognosis of lung transplant patients. AKI following lung transplantation can stem from multiple etiological factors, including hemodynamic instability, nephrotoxic medications, and the effects of ischemia-reperfusion injury during surgery [3,4]. The pathophysiology of AKI in this context is complex, involving renal perfusion issues and inflammatory responses that can lead to further organ dysfunction and increased morbidity [5,6]. Moreover, AKI is not merely a transient complication, it can lead to persistent renal impairment and significantly impact the overall health of the patient, necessitating a comprehensive approach to its prediction, prevention, and management. The identification of patients at risk for AKI is crucial, as early intervention can mitigate its effects. Factors such as older age, male sex, preoperative renal function, and the presence of comorbid conditions like pulmonary hypertension have been identified as significant predictors of AKI in lung transplant recipients [3,4]. Consequently, implementing preoperative risk assessments and postoperative monitoring strategies can enhance early detection and intervention, potentially improving outcomes for these patients. In terms of prevention, strategies such as optimizing fluid management, avoiding nephrotoxic agents, and employing remote ischemic conditioning have shown promise in reducing the incidence of AKI [7,8]. Additionally, the use of biomarkers for early detection of renal injury is an area of ongoing research, with studies indicating that novel biomarkers may provide more sensitive and specific means of identifying AKI before traditional methods [9,10]. In conclusion, while lung transplantation offers hope for patients with severe lung diseases, the associated risk of AKI poses a significant challenge. A thorough understanding of the risk factors, preventive measures, and management strategies for AKI is essential for improving patient outcomes and enhancing the overall success of lung transplantation. Main body Mechanisms of acute kidney injury (AKI) after lung transplantation AKI is a common and serious complication following lung transplantation, significantly impacting patient outcomes and graft survival. The mechanisms underlying the development of AKI post-lung transplantation are multifactorial, involving hemodynamic changes, inflammatory responses, and drug toxicity. Understanding these mechanisms is crucial for improving perioperative management and patient care. Hemodynamic changes Hemodynamic alterations play a critical role in the onset of AKI after lung transplantation. During the perioperative period, patients often experience significant fluctuations in blood pressure and cardiac output, which can lead to renal hypoperfusion. Factors such as severe hypotension, septic shock, and the use of extracorporeal membrane oxygenation (ECMO) are associated with increased risks of AKI [1]. For instance, a study indicated that severe hypotension and prolonged ECMO were independently linked to the development of severe AKI, emphasizing the importance of maintaining stable hemodynamics during and after the transplant procedure [2]. Furthermore, the use of veno-arterial ECMO has been shown to mitigate the risk of AKI compared to traditional cardiopulmonary bypass methods, suggesting that intraoperative support strategies can significantly influence renal outcomes [3]. Vasoplegia increases the incidence of AKI by threefold [11]. The interplay between renal perfusion and systemic hemodynamics is complex, as acute kidney injury can also exacerbate pulmonary complications, creating a vicious cycle of organ dysfunction [4]. Therefore, monitoring and optimizing hemodynamic parameters during lung transplantation is essential for preventing AKI and improving overall patient survival. Inflammatory response The inflammatory response is another pivotal mechanism contributing to AKI following lung transplantation. The surgical procedure itself, along with ischemia-reperfusion injury, can trigger a systemic inflammatory response that adversely affects multiple organ systems, including the kidneys. Elevated levels of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), have been observed in patients post-transplant, correlating with the severity of AKI [12]. Additionally, the release of mediators like osteopontin from injured kidney cells has been identified as a key factor in the development of acute lung injury secondary to AKI, illustrating the interconnectedness of organ injuries [4]. The inflammatory cascade not only contributes to renal damage but also exacerbates lung injury, highlighting the importance of understanding interorgan communication in the context of transplantation [5]. Strategies aimed at modulating the inflammatory response, such as the use of immunosuppressive agents and anti-inflammatory therapies, may help mitigate the risk of AKI and improve postoperative outcomes for lung transplant recipients. Drug toxicity Drug toxicity is a significant contributor to the development of AKI in lung transplant patients, particularly due to the use of nephrotoxic medications during the perioperative period. Commonly used immunosuppressants, such as calcineurin inhibitors (CNIs), have been associated with renal impairment, especially when used in high doses or in the presence of other risk factors like dehydration or preexisting renal dysfunction [13]. A retrospective study found that patients receiving CNIs had a higher incidence of AKI compared to those on alternative immunosuppressive regimens, underscoring the need for careful monitoring of renal function in this population [1]. Moreover, CNIs are variability, such as, Van Dommelen et al. shows intravenous (IV) vs. oral administration affects AKI risk [14]. The use of antibiotics and other medications during the perioperative period can further exacerbate renal injury, particularly in patients with underlying risk factors [15]. To minimize the risk of drug-induced AKI, it is essential to tailor immunosuppressive therapy based on individual patient risk profiles and to implement strategies for renal protection, such as dose adjustment and close monitoring of renal function [3]. Understanding the pharmacokinetics and potential nephrotoxic effects of medications used in lung transplantation is crucial for optimizing patient outcomes and preventing AKI. Risk factors Baseline renal function Baseline renal function is a crucial determinant in assessing the risk of AKI during and after surgical procedures. Studies indicate that patients with preexisting renal impairment face a significantly elevated risk of postoperative AKI, especially in high-risk surgeries such as lung transplantation or major orthopedic procedures. For instance, a retrospective study involving lung transplant patients revealed that those with lower baseline estimated glomerular filtration rates (eGFR) had increased rates of AKI postoperatively, with a direct correlation between the severity of preoperative renal dysfunction and the incidence of postoperative complications [1]. Additionally, the presence of chronic kidney disease (CKD) has been associated with a higher likelihood of adverse outcomes following surgery, emphasizing the need for careful preoperative assessment of renal function. The risk stratification based on baseline renal function can aid in tailoring perioperative management strategies, including the potential use of nephroprotective agents and closer monitoring of renal parameters post-surgery. Preoperative comorbidities Preoperative comorbidities significantly influence surgical outcomes, including the risk of AKI. The presence of multiple comorbid conditions, such as diabetes, hypertension, and cardiovascular diseases, has been shown to exacerbate the risk of renal complications during and after surgical interventions. For example, a study highlighted that patients with severe comorbidities, particularly those with a high Charlson Comorbidity Index, experienced worse outcomes in terms of AKI incidence and overall survival rates following lung transplantation [4]. Furthermore, the interplay between comorbidities and surgical stress can lead to a cascade of physiological responses that may impair renal perfusion and function. This necessitates a comprehensive preoperative evaluation to identify at-risk patients and implement appropriate interventions, such as optimizing medical management of comorbidities prior to surgery, which may mitigate the risk of postoperative complications, including AKI [3]. Surgical duration and blood loss The duration of surgery and the volume of intraoperative blood loss are critical risk factors that can significantly impact postoperative outcomes, including the development of AKI. Prolonged surgical times have been associated with increased rates of complications, including AKI, particularly in high-risk populations. A study examining hip fracture surgeries found that extended operative duration correlated with a higher incidence of superficial surgical site infections and other complications, underscoring the importance of efficient surgical techniques [16]. Additionally, excessive blood loss during surgery can lead to hemodynamic instability, further compromising renal perfusion and increasing the likelihood of AKI. For instance, patients undergoing major surgeries with significant blood loss were found to have a higher risk of postoperative renal impairment [17]. Therefore, strategies to minimize surgical duration and blood loss, such as employing advanced surgical techniques and optimizing intraoperative management, are essential to reduce the risk of AKI and improve overall patient outcomes. Other risks During surgery, if donor-recipient mismatch occurs, the donor-recipient height ratio is the sole factor predicting the need for lung transplant size adjustment. Donor lungs requiring volume reduction surgery are associated with a higher incidence of postoperative AKI [18]. The scarcity of donors and prolonged recipient waiting time increase AKI incidence by 12% for every additional 30 days of waiting [19]. For transplanted lungs that cannot recover due to chronic rejection or acute severe dysfunction, retransplantation increases AKI incidence by 2.25-fold [20]. A BMI >30 elevates AKI incidence by 2.1-fold and raises the risk of moderate to severe tricuspid regurgitation by 2.61-fold [8]. Both preoperative mechanical ventilation and preoperative ECMO significantly increase AKI incidence [21]. Predictive models Predictive models in medicine play a crucial role in improving patient outcomes by enabling clinicians to anticipate disease progression, treatment responses, and potential complications. These models can be broadly categorized into clinical scoring systems and the application of biomarkers, both of which aid in risk stratification and personalized medicine approaches. The integration of these predictive tools into clinical practice can enhance decision-making processes, optimize resource allocation, and ultimately lead to better patient management strategies. The development and validation of these models require rigorous research methodologies and robust clinical data to ensure their reliability and applicability in real-world settings. Clinical scoring systems Clinical scoring systems serve as vital tools for assessing patient risk and guiding treatment decisions across various medical disciplines. These systems typically utilize a combination of clinical parameters, laboratory results, and demographic information to generate a score that reflects the likelihood of specific outcomes, such as disease progression, complications, or mortality. For instance, in the context of lung transplantation, scoring systems have been developed to predict the risk of AKI postoperatively, which is a common complication associated with high morbidity and mortality rates [1]. The recent study shows a genotype-guided nomogram can be used to assess the risk of persistent AKI following LTx, nine predictors, including body mass index, thrombin time, tacrolimus initial concentration, rs757210, rs1799884, rs6887695, rs1494558, rs2069762 and rs2275913, the area under the receiver operating characteristic curve of the nomogram was 0.698 (95% CI: 0.542–0.855) indicating good model fit [22]. The use of such scoring systems allows clinicians to stratify patients based on their risk profiles, enabling targeted interventions and closer monitoring of high-risk individuals. Furthermore, these systems can facilitate communication among healthcare providers by standardizing assessments and improving the consistency of clinical decision-making. However, it is essential to recognize that the effectiveness of clinical scoring systems is contingent upon their validation in diverse populations and clinical settings, as well as their adaptability to evolving medical knowledge and practices. Application of biomarkers The application of biomarkers in clinical practice has revolutionized the approach to disease diagnosis, prognosis, and treatment monitoring. Biomarkers, which are measurable indicators of biological processes, can provide valuable insights into disease mechanisms and patient responses to therapy. For example, the identification of specific biomarkers associated with AKI has enhanced the ability to differentiate between various causes of kidney dysfunction, such as prerenal azotemia and acute tubular necrosis [23,24]. This differentiation is crucial for implementing appropriate management strategies and improving patient outcomes. Additionally, biomarkers can be utilized for risk stratification in conditions such as lung transplantation, where elevated levels of certain biomarkers have been linked to increased risks of complications like primary graft dysfunction and AKI [3]. Specific biomarkers associated with increased risk of complications include: elevated urinary neutrophil gelatinase-associated lipocalin (NGAL) levels (>150 ng/mL) within 6 h post-transplant are strongly predictive of AKI and primary graft dysfunction [25]. A combined tissue inhibitor of metalloproteinases-2 [TIMP-2] insulin-like growth factor-binding Protein 7 [IGFBP7] value >0.3 identifies high-risk patients for AKI progression within 12 h [26]. Serum cystatin C ≥1.5 mg/dL preoperatively correlates with a 3-fold increased AKI risk post-transplant [26]. These biomarkers enhance early intervention by detecting renal injury before serum creatinine rises. As research continues to uncover novel biomarkers and refine existing ones, their integration into clinical practice will likely expand, paving the way for more personalized and effective treatment approaches. However, the successful implementation of biomarker-based strategies necessitates ongoing validation studies, standardized testing protocols, and a comprehensive understanding of the underlying biological mechanisms to ensure their clinical utility and reliability. Prevention strategies Effective prevention strategies are crucial in minimizing complications associated with surgical procedures. This section discusses three key areas of focus: preoperative preparation, intraoperative monitoring and management, and early postoperative intervention. Preoperative preparation Preoperative preparation is essential for optimizing patient outcomes and minimizing surgical complications. A thorough assessment of the patient’s medical history, including comorbidities, medication use, and previous surgical history, is critical in identifying potential risks. Enhanced recovery pathways, which incorporate prehabilitation strategies, have been shown to improve postoperative outcomes by preparing patients physically and psychologically for surgery. Interventions such as smoking cessation, nutritional optimization, and physical conditioning can significantly reduce postoperative morbidity and facilitate quicker recovery [27]. Preoperative assessment of renal function, in addition to creatinine and blood urea nitrogen, for example, cystatin C and microalbuminuria can better reflect early renal damage compared to creatinine and blood urea nitrogen. Studies have shown cystation C is superior to creatinine for detecting subclinical renal dysfunction (eGFR decline <60 mL/min). Microalbuminuria: Urinary mALB >30 mg/24 h predicts postoperative AKI [26]. Routine preoperative biomarker panels improve risk stratification and inform perioperative management. Furthermore, implementing standardized protocols for preoperative assessments, such as the use of checklists, can enhance the completeness of preparation and reduce errors [28]. Studies have demonstrated that a structured preoperative triage system can effectively streamline the preparation process, ensuring that patients receive timely and appropriate instructions regarding their surgical procedure [29]. Additionally, psychological preparation is gaining recognition for its impact on surgical outcomes, as addressing patients’ anxieties and expectations can lead to improved postoperative recovery [30]. Overall, a comprehensive approach to preoperative preparation, encompassing medical, physical, and psychological aspects, is vital for enhancing surgical safety and efficacy. Intraoperative monitoring and management Intraoperative monitoring and management play a crucial role in preventing complications during surgery. Continuous hemodynamic monitoring is essential for detecting and addressing intraoperative hypotension, which is associated with increased risk of postoperative organ failure [31]. Strategies such as cardiac output-guided hemodynamic management have been shown to optimize fluid and medication administration, thereby improving patient outcomes [32]. Fluid volume is closely associated with AKI occurrence. One study demonstrated that perioperative fluid positive balance not only increases AKI incidence but also elevates 30-day mortality [33]. Another study also proved that maintaining fluid negative balance in the early postoperative period may have a protective effect on renal function [34]. Additionally, the use of advanced monitoring technologies, such as nociception monitoring tools, can help tailor analgesia during surgery, reducing opioid consumption and minimizing side effects [35]. The implementation of protocols for managing intraoperative blood pressure and ensuring adequate organ perfusion is critical, particularly in high-risk patients [31]. Furthermore, the choice of anesthetic agents and techniques can significantly influence intraoperative stability and postoperative recovery. For instance, the use of regional anesthesia may reduce the need for systemic opioids and enhance recovery [36]. Thus, meticulous intraoperative monitoring and management are essential for mitigating risks and ensuring optimal outcomes. Early postoperative intervention Early postoperative intervention is vital for enhancing recovery and preventing complications following surgery. Implementing early mobilization protocols has been associated with reduced postoperative complications and improved functional recovery [37]. Studies indicate that patients who engage in early physical activity experience shorter hospital stays and better overall satisfaction with their recovery process [38]. Additionally, early identification and management of complications, such as postoperative pancreatic fistula, can significantly impact patient outcomes. Utilizing early risk stratification tools based on postoperative laboratory values enables timely interventions that can prevent severe complications [39]. Furthermore, incorporating patient education and support systems post-surgery can enhance adherence to recovery protocols and improve overall patient satisfaction [40]. Overall, prioritizing early postoperative interventions is crucial for facilitating recovery, minimizing complications, and improving long-term outcomes for surgical patients. Management methods Management of AKI is critical in clinical settings, particularly in patients undergoing high-risk procedures such as lung transplantation. Effective management strategies encompass grading and assessment of AKI, appropriate indications for dialysis treatment, and long-term follow-up with kidney function monitoring. Grading and assessment of AKI The assessment of AKI is primarily based on the Kidney Disease: Improving Global Outcomes (KDIGO) criteria, which classify AKI into three stages based on serum creatinine levels and urine output. This classification system is crucial for determining the severity of kidney injury and guiding treatment decisions. Studies indicate that the KDIGO classification has strong predictive value for long-term outcomes in various patient populations, including those with diffuse proliferative lupus nephritis and septic patients. Biomarkers can also effectively predict and assess AKI, if urinary NGAL >400 ng/mL, AKI severity is Stage 3; urinary IL-18 > 100 pg/mL discriminates intrinsic AKI from prerenal causes; TIMP-2/IGFBP7 plus furosemide stress test (FST) improves AKI staging accuracy [23,26]. For instance, in a cohort of patients with AKI, the severity of the injury was significantly associated with outcomes such as progression to end-stage renal disease (ESRD) and overall mortality rates [41,42]. Furthermore, the use of biomarkers and imaging techniques is recommended to enhance the accuracy of AKI diagnosis and to monitor kidney function recovery post-injury. Continuous assessment through serum creatinine measurements and urine output monitoring is essential for timely intervention and management of AKI, particularly in critically ill patients and those undergoing complex surgeries such as lung transplantation [2,43]. Indications for dialysis treatment Dialysis is an essential therapeutic option for patients with severe AKI, particularly when conservative management fails to restore kidney function or when life-threatening complications arise. The indications for initiating dialysis include severe metabolic derangements, fluid overload unresponsive to diuretics, and symptomatic uremia. In the context of lung transplantation, AKI is a common complication, with studies showing that up to 71.7% of lung transplant recipients experience some degree of AKI postoperatively [1]. The decision to start dialysis should be individualized, taking into account the patient’s clinical status, the severity of kidney injury, and the presence of comorbidities. For instance, patients requiring renal replacement therapy (RRT) post-lung transplantation have been shown to have significantly poorer outcomes, emphasizing the importance of timely intervention [3,7]. The use of continuous renal replacement therapy is often preferred in critically ill patients due to its ability to provide gradual fluid and solute removal, minimizing hemodynamic instability [44,45]. Long-term follow-up and kidney function monitoring Long-term follow-up and monitoring of kidney function are critical for patients who have experienced AKI, especially those with risk factors for CKD. Studies indicate that a significant proportion of patients who suffer from AKI may develop persistent renal impairment, with follow-up assessments revealing high rates of CKD among survivors of severe AKI episodes [46,47]. Regular monitoring of renal function through serum creatinine levels and estimated glomerular filtration rate (eGFR) is recommended, particularly in high-risk populations such as those with a history of AKI or those undergoing major surgeries like lung transplantation. Furthermore, the integration of nephrology consultations during hospital stays has been shown to improve post-discharge monitoring rates, highlighting the importance of multidisciplinary approaches in managing patients with a history of AKI [48,49]. As kidney function can decline over time, especially in patients with comorbid conditions, proactive follow-up strategies are essential for early detection and management of potential long-term complications. Kidney histopathology Renal failure after lung transplantation is a common complication, with a 15.8% incidence of severe CKD within 5 years. The occurrence rate of acute kidney injury (AKI) in lung transplant recipients is 52%, among which 9% of patients require dialysis. Therefore, renal biopsy is crucial for early diagnosis of kidney injury post-lung transplantation, as renal diseases negatively impact prognosis. Renal biopsies reveal extensive chronic lesions involving glomeruli, blood vessels, and tubulointerstitium. The most common final diagnoses include atherosclerosis, acute CNI toxicity, thrombotic microangiopathy, and acute tubular necrosis. Postoperative dialysis, proteinuria >3 g/24 h, and glomerulosclerosis percentage >4% are independent risk factors for ESRD [50]. Patient-Reported outcomes Follow-up monitoring of lung transplant patients with AKI serves as a crucial measure and methodology for investigating their short-term and long-term quality of life. Current short-term outcomes indicate that lung transplant AKI patients exhibit significantly prolonged ICU stays, extended durations of mechanical ventilation, and 5–9% require RRT treatment, with notable increases in both hospitalization costs and duration. No literature has yet reported on their long-term quality of life, which will constitute a key focus of our future research [21,23]. Conclusion AKI following lung transplantation remains a multifaceted clinical challenge, influenced by a myriad of mechanisms and risk factors. The interplay between surgical stress, ischemia-reperfusion injury, and the systemic effects of immunosuppression creates a complex environment where patients are at heightened risk for renal dysfunction. Our review has highlighted the necessity of employing effective predictive tools, preventative measures, and management strategies to mitigate the incidence of AKI in this vulnerable population. From an expert perspective, it is crucial to balance the diverse research findings that emerge from various studies focusing on the pathophysiology of AKI in lung transplant recipients. While some studies emphasize the role of hemodynamic changes and nephrotoxic agents, others explore the genetic predispositions and inflammatory responses associated with renal injury. Integrating these perspectives is vital for developing comprehensive risk stratification models that can aid clinicians in identifying patients who are at greater risk for AKI. Moreover, the advancement of novel biomarkers presents an exciting frontier in the early detection and management of AKI. Future research should prioritize the identification and validation of these biomarkers, which may offer insights into the renal recovery process and guide therapeutic interventions. The clinical application of these biomarkers could significantly enhance our understanding of AKI dynamics, leading to tailored strategies that optimize patient outcomes post-transplant. AKI is an important aspect of future research in lung transplantation, encompassing fundamental medical studies such as the ischemia-reperfusion injury pathway and the construction of lung-kidney interaction models; translational medicine involving biomarker combinations (e.g., cfDNA + NGAL) for predicting AKI and multicenter validation; as well as multicenter clinical studies on the relationship between immunosuppressive drugs CNI and AKI. In conclusion, addressing AKI after lung transplantation requires a collaborative approach that incorporates multidisciplinary insights and innovative methodologies. By fostering a deeper understanding of the underlying mechanisms and leveraging emerging technologies, the medical community can improve the prevention and management of AKI, ultimately enhancing the postoperative recovery trajectories of lung transplant recipients. Future studies should continue to explore the intricate relationships between various risk factors and clinical outcomes, paving the way for evidence-based practices that can transform patient care in this critical area of transplantation medicine.